Mixed Hepatocellular Cholangiocarcinoma and Intrahepatic Cholangiocarcinoma in Patients Undergoing Transplantation for Hepatocellular Carcinoma

被引:128
|
作者
Sapisochin, Gonzalo [1 ,2 ]
Fidelman, Nicholas
Roberts, John P. [1 ]
Yao, Francis Y. [1 ]
机构
[1] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA
[2] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Hepatobiliary & Pancreat Surg & Transplantat, E-08193 Barcelona, Spain
关键词
LIVER-TRANSPLANTATION; UNITED-STATES; CIRRHOSIS; RESECTION;
D O I
10.1002/lt.22307
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Mixed hepatocellular cholangiocarcinoma (HCC-CC) and intrahepatic cholangiocarcinoma (I-CC) are increasingly being reported in patients with cirrhosis. The aims of this study were (1) to evaluate the incidence, imaging features, and posttransplant outcomes for patients who underwent transplantation for hepatocellular carcinoma (HCC) and were found to have HCC-CC or I-CC in the explant and (2) to compare the outcomes of these patients with those of controls with HCC who were matched (1:3) by the tumor size and the number of nodules in the explant. In the explant specimens of 10 of 302 patients (3.3%) who underwent liver transplantation (LT) for HCC, mixed HCC-CC or I-CC was identified. There were 4 additional incidental cases of HCC-CC. After a median follow-up period of 32 months, 8 of the 14 patients (57%) suffered from tumor recurrence, and the median disease-free survival time was 8 months. The cumulative risk of tumor recurrence was 40% and 70% at 1 and 5 years, respectively, for these 14 patients. When the 4 incidental cases were excluded, the study group with HCC-CC or I-CC (n = 10) had a significantly lower incidence of well-differentiated tumors (11.1% versus 43.3%, P < 0.02) and a higher rate of recurrence (60% versus 16.7%, P = 0.008) in comparison with the control group of patients with HCC (n = 30). The 1- and 5-year cumulative risks of tumor recurrence were 42% and 65%, respectively, in the study group and 10% and 17%, respectively, in the control group (P < 0.002). The actuarial 1- and 5-year patient survival rates without recurrence were also significantly lower in the study group (79% and 32% in the study group and 90% and 62% in the control group, P < 0.03). Dynamic contrast-enhanced computed tomography or magnetic resonance imaging showed progressive contrast enhancement throughout the arterial and portal venous phases without washout in 8 of the 10 patients. In conclusion, HCC-CC and I-CC are associated with a poor prognosis and a high rate of tumor recurrence after LT, and both tumors exhibit radiographic features that are distinct from those observed with HCC. Liver Transpl 17:934-942, 2011. (C) 2011 AASLD.
引用
收藏
页码:934 / 942
页数:9
相关论文
共 50 条
  • [31] Intrahepatic cholangiocarcinoma diagnosed preoperatively as hepatocellular carcinoma
    Yamamoto, M
    Ariizumi, S
    Otsubo, T
    Katsuragawa, H
    Katagiri, S
    Nakano, M
    Takasaki, K
    JOURNAL OF SURGICAL ONCOLOGY, 2004, 87 (02) : 80 - 83
  • [32] Transarterial radioembolization of hepatocellular carcinoma and intrahepatic cholangiocarcinoma
    Helmberger, Thomas
    Pereira, Philippe L.
    RADIOLOGIE, 2022, 62 (03): : 234 - 238
  • [33] Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Outcome After Liver Transplantation
    Kishore Maganty
    David Levi
    Jang Moon
    Pablo A. Bejarano
    Leopoldo Arosemena
    Andreas Tzakis
    Paul Martin
    Digestive Diseases and Sciences, 2010, 55 : 3597 - 3601
  • [34] MIXED HCC-CHOLANGIOCARCINOMA AND INTRAHEPATIC CHOLANGIOCARCINOMA IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HCC
    Dayangac, Murat
    Bozkurt, Birkan
    Balci, Cem
    Dogusoy, Gulen
    Tokat, Yaman
    TRANSPLANT INTERNATIONAL, 2017, 30 : 285 - 285
  • [35] Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Outcome After Liver Transplantation
    Maganty, Kishore
    Levi, David
    Moon, Jang
    Bejarano, Pablo A.
    Arosemena, Leopoldo
    Tzakis, Andreas
    Martin, Paul
    DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (12) : 3597 - 3601
  • [36] Surgical treatment of patients with mixed hepatocellular carcinoma and cholangiocarcinoma
    Nakamura, S
    Suzuki, S
    Sakaguchi, T
    Serizawa, A
    Konno, H
    Baba, S
    Baba, S
    Muro, H
    CANCER, 1996, 78 (08) : 1671 - 1676
  • [37] Surgical treatment of patients with mixed hepatocellular carcinoma and cholangiocarcinoma
    Maeda, T
    Tsuneyoshi, M
    Takenaka, K
    Sugimachi, K
    CANCER, 1997, 80 (03) : 514 - 515
  • [38] Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma
    Mitsumaro Itoyama
    Masaki Hata
    Koji Yamanegi
    Naoko Yamada
    Hideki Ohyama
    Hiroshi Hirano
    Nobuyuki Terada
    Keiji Nakasho
    Medical Molecular Morphology, 2012, 45 : 7 - 13
  • [39] Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma
    Itoyama, Mitsumaro
    Hata, Masaki
    Yamanegi, Koji
    Yamada, Naoko
    Ohyama, Hideki
    Hirano, Hiroshi
    Terada, Nobuyuki
    Nakasho, Keiji
    MEDICAL MOLECULAR MORPHOLOGY, 2012, 45 (01) : 7 - 13
  • [40] Morphomolecular Classification Update on Hepatocellular Adenoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma
    Katabathina, Venkata S.
    Khanna, Lokesh
    Surabhi, Venkateswar R.
    Minervini, Marta
    Shanbhogue, Krishna
    Dasyam, Anil K.
    Prasad, Srinivasa R.
    RADIOGRAPHICS, 2022, 42 (05) : 1338 - 1357